Skip to content
OpenCapital
Get started

NuSkin Enterprises NUS Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

USANA Health Sciences logo
USANA Health SciencesUSNA
$4.42M+306%
Herbalife logo
HerbalifeHLF
——

Other financials

Income statement

See full
Revenue$320.6M-12.0%
Gross profit$214.5M-13.2%
Operating income$4.0M+141%
Net income$1.8M-98.3%
EPS (diluted)$0.04-98.1%

Balance sheet

See full
Cash & equivalents$198.7M-2.5%
Total debt$303.6M-8.2%
Total equity$794.1M+5.3%
Total assets$1.4B-1.1%

Cash flow

See full
Operating cash flow-$3.9M-1,107%
CapEx$13.7M+1.0%
Free cash flow-$17.6M-33.6%

Valuation

See full
Market cap$256.35M-38.2%

Where this comes from

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NuSkin Enterprises's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
NuSkin Enterprises (NUS) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of -$39.98M in Q1 2026.
How has NuSkin Enterprises's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
NuSkin Enterprises's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation decreased by 336.7% year-over-year, from $16.89M to -$39.98M.